These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10780333)

  • 21. [Current knowledge on von Willebrand's disease].
    Fukui H
    Rinsho Ketsueki; 1988 Nov; 29(11):1980-90. PubMed ID: 3070071
    [No Abstract]   [Full Text] [Related]  

  • 22. Peri-operative management of an adult patient with type 2N von Willebrand's disease scheduled for coronary artery bypass graft.
    Gerling V; Lahpor JR; Buhre W
    Anaesthesia; 2007 Apr; 62(4):405-8. PubMed ID: 17381580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Successful treatment of severe hemorrhage by using thrombocyte suspension with cryoprecipitate in type III Willebrand disease].
    Boda Z; Pfliegler G; Hársfalvi J; Rák K
    Orv Hetil; 1991 Nov; 132(45):2499-502. PubMed ID: 1945395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa.
    Meijer K; Peters FT; van der Meer J
    Blood Coagul Fibrinolysis; 2001 Apr; 12(3):211-3. PubMed ID: 11414636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology.
    Eikenboom JC
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):365-79. PubMed ID: 11686105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease.
    Boyer-Neumann C; Dreyfus M; Wolf M; Veyradier A; Meyer D
    J Thromb Haemost; 2003 Jan; 1(1):190-2. PubMed ID: 12871560
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to von Willebrand factor in von Willebrand disease.
    Mannucci PM; Federici AB
    Adv Exp Med Biol; 1995; 386():87-92. PubMed ID: 8851017
    [No Abstract]   [Full Text] [Related]  

  • 29. [The pathogenesis of acquired von Willebrand's disease in a patient with asymptomatic monoclonal gammopathy; malignant lymphoma developing 30 months after onset of bruising].
    Takai Y; Hayasi H; Tsurumi N; Tsuda T; Fujlta T; Ohnoshi T; Kimura I
    Rinsho Ketsueki; 1987 Jan; 28(1):53-64. PubMed ID: 3494863
    [No Abstract]   [Full Text] [Related]  

  • 30. [Von Willebrand's disease, with special reference to laboratory diagnosis (the ristomycin test)].
    Boda Z; Rák K
    Orv Hetil; 1980 Oct; 121(42):2563-7. PubMed ID: 6258126
    [No Abstract]   [Full Text] [Related]  

  • 31. Recombinant factor VIIa (NovoSeven) for post-prostatectomy hemorrhage in a patient with type I von Willebrand disease.
    Tarantino MD; Aberle R
    Am J Hematol; 2001 Sep; 68(1):62-3. PubMed ID: 11559941
    [No Abstract]   [Full Text] [Related]  

  • 32. Acquired von Willebrand disease: management of labor and delivery with intravenous dexamethasone, continuous factor concentrate, and immunoglobulin infusion.
    Lipkind HS; Kurtis JD; Powrie R; Carpenter MW
    Am J Obstet Gynecol; 2005 Jun; 192(6):2067-70. PubMed ID: 15970901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Severe epistaxis in hemorrhagic syndromes (excepting Rendu-Osler disease)].
    Josso F
    Ann Otolaryngol Chir Cervicofac; 1976; 93(1-2):15-21. PubMed ID: 788610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease.
    van Genderen PJ; Terpstra W; Michiels JJ; Kapteijn L; van Vliet HH
    Thromb Haemost; 1995 May; 73(5):891-2. PubMed ID: 7482422
    [No Abstract]   [Full Text] [Related]  

  • 35. Childhood haemostasis III: von Willebrand's disease.
    Han P
    J Singapore Paediatr Soc; 1988; 30(1-2):46-50. PubMed ID: 3062271
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of recombinant factor VIIa in inherited and acquired von Willebrand disease.
    Sucker C; Scharf RE; Zotz RB
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):27-31. PubMed ID: 18263636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intramural duodenal hematoma in a child with von Willebrand's disease].
    Osipov AP; Mal'tsev VA; Tolkachev IuV
    Vestn Khir Im I I Grek; 1990 Oct; 145(10):81-2. PubMed ID: 1964305
    [No Abstract]   [Full Text] [Related]  

  • 38. Acquired von Willebrand's syndrome. Therapeutic and diagnostic implications.
    Brownlee RE; Shockley WW
    Arch Otolaryngol Head Neck Surg; 1991 Jan; 117(1):106-8. PubMed ID: 1986754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
    Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
    Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intermittent thrombocytopenia as a manifestation of Von Willebrand's disease].
    Gómez García EB; Brouwers GJ; Kappers-Klunne MC; Leebeek FW; van Vliet HH
    Ned Tijdschr Geneeskd; 2002 Jun; 146(25):1192-5. PubMed ID: 12109311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.